Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dilmapimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 known ✓ | Q16539 | 13/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 8/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 7/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 7/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | CTSA | P10619 | 3/20 | 0.35 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.33 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.33 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.33 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.32 |
| ▸ | STK26 | Q9P289 | 1/20 | 0.32 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dilmapimod SCHEMBL29528002 | 1.00 | MAPK14 (0.47) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| Dilmapimod SCHEMBL29372394 | 1.00 | MAPK14 (0.47) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| Dilmapimod SCHEMBL29379709 | 1.00 | MAPK14 (0.47) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL1061169 | 0.94 | MAPK14 (0.40) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL21133793 | 0.93 | MAPK14 (0.41) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL1065110 | 0.92 | MAPK14 (0.47) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL1066023 | 0.92 | MAPK14 (0.47) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| SCHEMBL1065108 | 0.92 | MAPK14 (0.47) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| Dilmapimod SCHEMBL30241080 | 0.91 | MAPK14 (0.41) | MAPK14MAPK11MAPK13MAPK12KCNH2 | |
| Dilmapimod SCHEMBL4943074 | 0.91 | MAPK14 (0.41) | MAPK14MAPK11MAPK13MAPK12KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3478322-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | hVIVO Services Limited (GB) | 2019-05-08 | — | — | EP | claimed |
| WO-2018007788-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | HVIVO SERVICES LIMITED (GB) | 2018-01-11 | — | — | WO | claimed |
| WO-2014122298-A1 | INTERLEUKIN-4 INHIBITORS FOR THE TREAMTENT OF NEUTROPENIA | Universität Zürich (CH) | 2014-08-14 | — | — | WO | claimed |
| EP-2404603-A1 | Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds for the treatment of CSBP/p38 kinase mediated diseases | Glaxosmithkline LLC (US) | 2012-01-11 | — | — | EP | claimed |
| EP-1333833-B1 | Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compound for the treatment of CSBP/p38 kinase mediated diseases | GLAXOSMITHKLINE LLC (US) | 2011-08-24 | — | — | EP | claimed |
| US-20110009625-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-01-13 | — | — | US | claimed |
| US-20100069409-A1 | \"NOVEL COMPOUNDS\ | GLAXO GROUP LIMITED (GB) | 2010-03-18 | — | — | US | claimed |
| US-20090074676-A1 | Inhibition of p38 MAPK For Treatment Of Obesity | SMITHKLINE BEECHAM CORPORATION | 2009-03-19 | — | — | US | claimed |
| US-20080268044-A1 | Novel Process and Formulations | GLAXO GROUP LIMITED | 2008-10-30 | — | — | US | claimed |
| EP-1954282-A2 | NOVEL PROCESS AND FORMULATIONS | GLAXO GROUP LIMITED (GB) | 2008-08-13 | — | — | EP | claimed |
| US-20080033170-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2008-02-07 | — | — | US | claimed |
| US-7314881-B2 | 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-01 | — | — | US | claimed |
| WO-2007059500-A2 | NOVEL PROCESS AND FORMULATIONS | GLAXO GROUP LIMITED (GB) | 2007-05-24 | — | — | WO | claimed |
| US-20050203109-A1 | Novel Compounds | SMITHKLINE BEECHAM CORPORATION | 2005-09-15 | — | — | US | claimed |
| US-20040209901-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2004-10-21 | — | — | US | claimed |
| US-20040116697-A1 | Novel compounds | GLAXOSMITHKLINE LLC | 2004-06-17 | — | — | US | claimed |
| WO-2024150014-A1 | MEDICINAL PRODUCTS AND METHODS FOR THE ALLEVIATION OF CANCER IMMUNOTHERAPY-ASSOCIATED CYTOKINE RELEASE SYNDROME | Poolbeg Pharma (UK) Limited (GB) | 2024-07-18 | — | — | WO | disclosed |
| US-20230263803-A1 | METHODS OF PREVENTING OR TREATING COVID-19 AND RELATED VIRAL DISEASES OR DISORDERS | KINARUS AG (CH) | 2023-08-24 | — | — | US | disclosed |
| US-20040209901-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2004-10-21 | — | — | US | disclosed |
| US-20040116697-A1 | Novel compounds | GLAXOSMITHKLINE LLC | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033170-A1 | NOVEL COMPOUNDS | MAPKAPK2, CREBBP, CDC42BPB | MAPK14 42/4885MAPK11 94/4885MAPK13 43/4885 |
| US-20100069409-A1 | \"NOVEL COMPOUNDS\ | MAPKAPK2, CDC42BPB, MAP4K2 | MAPK14 60/4885MAPK11 89/4885MAPK13 58/4885 |
| US-20230263803-A1 | METHODS OF PREVENTING OR TREATING COVID-19 AND RELATED VIRAL DISEASES OR DISORDERS | PPARA, PPARD, PPARG | MAPK14 85/4885MAPK11 26/4885MAPK13 33/4885 |
| US-20090074676-A1 | Inhibition of p38 MAPK For Treatment Of Obesity | MAPKAPK2, MAPK1, MAPK6 | MAPK14 16/4885MAPK11 13/4885MAPK13 15/4885 |
| US-20080268044-A1 | Novel Process and Formulations | UGT1A7, UGT2B7, CYP3A7 | MAPK14 2969/4885MAPK11 2124/4885MAPK13 2574/4885 |
| US-20110009625-A1 | NOVEL COMPOUNDS | MAPKAPK2, CREBBP, CDC42BPB | MAPK14 42/4885MAPK11 94/4885MAPK13 43/4885 |
| US-20040209901-A1 | Novel compounds | MAPKAPK2, MAPKAPK3, MAPK7 | MAPK14 22/4885MAPK11 52/4885MAPK13 25/4885 |
| US-20050203109-A1 | Novel Compounds | MAPKAPK2, CREBBP, CDC42BPB | MAPK14 42/4885MAPK11 94/4885MAPK13 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.